Consolidated Statements of Comprehensive Loss (USD $) In Thousands, except Share data, unless otherwise specified	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Revenues:
Clinical treatment programs	$ 36	$ 36	$ 112	$ 78
Total revenues	36	36	112	78
Costs and expenses:
Production/cost of goods sold	294	635	617	826
Research and development	2,330	2,318	4,656	4,654
General and administrative	2,497	1,817	5,036	3,894
Total costs and expenses	5,121	4,770	10,309	9,374
Operating loss	(5,085)	(4,734)	(10,197)	(9,296)
Interest expense	(3)	(5)	(6)	(10)
Interest and other income	131	354	284	535
Gain from sale of income tax net operating losses	0	0	1,126	686
Redeemable warrants valuation adjustment	1	102	1	191
Net loss	(4,956)	(4,283)	(8,792)	(7,894)
Other Comprehensive Income (Loss):
Unrealized gain (loss) on marketable securities	147	(1,005)	168	(960)
Reclassification adjustments for impairment losses included in net loss	0	(76)	0	(85)
Net comprehensive loss	$ (4,809)	$ (5,364)	$ (8,624)	$ (8,939)
Basic and diluted loss per share (usd per share)	$ (0.03)	$ (0.03)	$ (0.05)	$ (0.05)
Weighted average shares outstanding, basic and diluted (shares)	185,749,722	167,202,512	181,265,253	167,005,714